|
|
|||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
Rifabutin and Antiretroviral DrugsRifabutin is as effective for tuberculosis treatment as rifampin 38, 39, but has much less effect on drugs metabolized through the CYP3A system 40 (Table 3). However, rifabutin is either not available or is very expensive in countries with high rates of HIV-related tuberculosis. Furthermore, some antiretroviral drugs have a substantial effect on rifabutin concentrations, necessitating somewhat complex dosing guidelines for rifabutin in the setting of antiretroviral therapy (see Table 3). In addition to their complexity, there is another potential problem of using rifabutin for tuberculosis treatment. If a patient whose rifabutin dose was decreased in response to antiretroviral therapy then stops taking the interacting drug (e.g., ritonavir), the resulting rifabutin concentrations are likely to be sub-therapeutic. These factors, in addition to the limited availability of the drug, limit the use of rifabutin in the treatment of HIV-related tuberculosis. Rifabutin and Protease InhibitorsRifabutin has little, if any effect on the serum concentrations of protease-inhibitors (other than unboosted saquinavir) 22. Cohort studies have shown favorable virological and immunological outcomes of protease-inhibitor-based antiretroviral therapy in the setting of rifabutin-based tuberculosis treatment 1, 41. Though no comparative studies have been done, the combination of rifabutin (if available) with protease-inhibitor based antiretroviral therapy is the preferred form of therapy for patients unable to take NNRTI-based antiretroviral therapy (Table 1). As above, there are concerns about the safety of super-boosted protease-inhibitors and the efficacy of nucleoside-only regimens in the setting of rifampin-based tuberculosis treatment. The protease-inhibitors, particularly if pharmacologically boosted with ritonavir, markedly increase serum concentrations and toxicity of rifabutin 42. Therefore, the dose of rifabutin should be decreased when used with protease-inhibitors (Table 3). As above, the decreased dose of rifabutin would be sub-therapeutic if the patient stopped taking the protease-inhibitor without adjusting the rifabutin dose. Therefore, adherence to the protease-inhibitor should be assessed with each dose of directly observed tuberculosis treatment; one convenient way to do so is to give a supervised dose of protease-inhibitor at the same time as the directly observed dose of tuberculosis treatment.
Last Reviewed: 05/18/2008 |
|||
|
If you would like to order any of the DTBE publications please visit the online order form. You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat™ Reader. If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available. Division of Tuberculosis Elimination
Centers for Disease Control & Prevention |